Neurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment

MT Newswires Live12-21 00:53

Neurocrine Biosciences (NBIX) Friday morning said its Crenessity drug therapy is now commercially available as an adjunctive treatment for congenital adrenal hyperplasia in adults and children aged four years and older following the US Food and Drug Administration approval earlier this month.

Crenessity is the first new treatment for congenital adrenal hyperplasia in 70 years. The drug works by controlling the overproduction of adrenal androgens, which cause the early appearance of male characteristics, thus allowing for reduced glucocorticoid use, according to the company.

As part of the launch, Neurocrine partnered with PANTHERx Rare, a specialty pharmacy, to streamline the prescription process for Crenessity and help patients secure insurance coverage.

The company said it expects 90% of patients will pay $12 or less per month for the medication.

Neurocrine shares were rising more than 1% in Friday's late-morning trade.

Price: 136.52, Change: +1.55, Percent Change: +1.15

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493262064?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-21 00:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493262064","market":"sg","top_or_hot":-1,"title":"Neurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment","media":"MT Newswires Live","content":"<html><body><p> Neurocrine Biosciences (NBIX) Friday morning said its Crenessity drug therapy is now commercially available as an adjunctive treatment for congenital adrenal hyperplasia in adults and children aged four years and older following the US Food and Drug Administration approval earlier this month.</p><p>Crenessity is the first new treatment for congenital adrenal hyperplasia in 70 years. The drug works by controlling the overproduction of adrenal androgens, which cause the early appearance of male characteristics, thus allowing for reduced glucocorticoid use, according to the company.</p><p>As part of the launch, Neurocrine partnered with PANTHERx Rare, a specialty pharmacy, to streamline the prescription process for Crenessity and help patients secure insurance coverage.</p><p>The company said it expects 90% of patients will pay $12 or less per month for the medication.</p><p>Neurocrine shares were rising more than 1% in Friday's late-morning trade.</p><p>Price: 136.52, Change: +1.55, Percent Change: +1.15</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-21 00:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neurocrine Biosciences (NBIX) Friday morning said its Crenessity drug therapy is now commercially available as an adjunctive treatment for congenital adrenal hyperplasia in adults and children aged ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NBIX","symbol_name":"神经分泌生物科学","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493262064","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493262064","pubTimestamp":1734713596,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurocrine Biosciences (NBIX) Friday morning said its Crenessity drug therapy is now commercially available as an adjunctive treatment for congenital adrenal hyperplasia in adults and children aged fo","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NBIX":"神经分泌生物科学"},"translate_title":"Neurocrine Biosciences开始商业化销售新型先天性肾上腺增生疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1},"content_text":"Neurocrine Biosciences (NBIX) Friday morning said its Crenessity drug therapy is now commercially available as an adjunctive treatment for congenital adrenal hyperplasia in adults and children aged four years and older following the US Food and Drug Administration approval earlier this month.Crenessity is the first new treatment for congenital adrenal hyperplasia in 70 years. The drug works by controlling the overproduction of adrenal androgens, which cause the early appearance of male characteristics, thus allowing for reduced glucocorticoid use, according to the company.As part of the launch, Neurocrine partnered with PANTHERx Rare, a specialty pharmacy, to streamline the prescription process for Crenessity and help patients secure insurance coverage.The company said it expects 90% of patients will pay $12 or less per month for the medication.Neurocrine shares were rising more than 1% in Friday's late-morning trade.Price: 136.52, Change: +1.55, Percent Change: +1.15","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493262064"}